The emergence of medications like copyright and Semaglutide signifies a major shift in how we manage metabolic disorders. These groundbreaking therapies belong to a class known as GLP-1 action agonists, which replicate the effects of a natural hormone that manages glucose levels and food intake. Initially, developed for managing blood sugar, their